Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A phase II multi-institutional Study evaluating the safety and efficacy of the combination of lisocabtagene maraleucel and zanubrutinib in patients with richter transformation

View Full Paper
Ask AI
Bookmark
Share

Authors

LRLindsey RikeSHS. R. HintonCHCorinne Hoffman

Discussion

Loading...

Member takes

Overview

Multicenter study assesses improved outcomes in richter transformation using CAR-T and BTK inhibitors, highlighting response rates and safety.

Key Points

  • Evaluate the safety and efficacy of zanubrutinib and liso-cel in patients with Richter transformation.
  • Phase II multicenter study
  • Inclusion of patients with confirmed Richter transformation and chronic lymphocytic leukemia
  • Combination treatment with zanubrutinib and CAR-T therapy
  • Assessment of overall response rates and adverse events
  • Target overall response rate of 60% for the treatment combination
  • Evaluation of safety and adverse events associated with the therapy
  • Mean progression free survival expected to improve with combination therapy

Cite This Study

Rike et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d655https://doi.org/10.1182/blood-2025-1953
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Correlates of response to combined checkpoint and BTK inhibition for treatment of richter transformation: Extended follow-up from the prospective RT1 trial2025
  2. 2Rituximab, lenalidomide, and zanubrutinib (ZR2) with sequential CAR-T cell as first-line therapy for high-risk large B cell lymphoma2025
  3. 3Trial in progress: Treatment of CNS lymphoma with zanubrutinib and tislelizumab: A phase ib/II investigator-initiated study2025
  4. 4Pirtobrutinib, venetoclax, and obinutuzumab for patients with richter transformation: A phase 2 trial2025
  5. 5Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma2026